Skip to main content
SpringerLink
Log in

Cellular responses of mammary carcinomas to aromatase inhibitors: Effects of vorozole

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Vorozole (Vz) is a competitive non-steroidal inhibitor of aromatase, which has been used to treat breast cancer in postmenopausal women and in various chemoprevention pre-clinical studies. Recently, we assessed the inhibitory effect of Vz on Mnu-induced mammary carcinogenesis (Lubet et al., 1994), as well as on the progression of mammary tumors (Lubet et al., 1998). In this study we evaluated the effects of Vz on tumor growth, serum estradiol, cell proliferation, apoptotic and non-apoptotic cell death to determine whether any of these 'surrogate’ markers might reflect the efficacy of various doses of Vz. Vz at doses of 2.5 (Hi), 0.32 (Md), and 0.08 (Lo) mg/kg body weight induced complete (100%), 60%, and 20% regression of mammary tumors, respectively. Vz at Hi and Md doses caused a decrease in serum estradiol within the first two days of treatment, and the estradiol values remained low with additional treatment for 4 and 10 days. When Vz was administered to animals bearing palpable tumors a time and dose-dependent decrease in the proliferating cells (BrdU-LI) was observed. The percentage of apoptotic cells (Al) sharply increased 2 days after initiation of Vz treatment and then decreased followed by an increase in non-apoptotic dead cells. Interestingly even the Lo dose of Vz, which was only moderately effective in suppressing tumor growth, decreased cell proliferation and increased cell death in the peripheral tumor areas at 4 and 10 days after initiation of treatment. The time- and dose-dependent alterations in various cell parameters suggest two different phases of Vz-induced cellular responses: (1) an early phase (2–4 days of treatment) with a sharp increase in apoptotic cells and decrease in proliferating cells, and (2) a later phase (10 days) with disintegration of tumor parenchyma, increase in non-apoptotic dead cells, and decrease in apoptotic cells. The dose-dependent decrease in proliferating cells and increase in apoptotic and non-apoptotic cell death in Vz-treated animals suggest that these biomarkers might be used as potential surrogate endpoints for efficacy in breast cancer chemoprevention and therapy studies with aromatase inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Buzdar AU, Hortobagyi G: Update on endocrine therapy for breast cancer. Clin Cancer Res 4: 527–534, 1998

    Google Scholar 

  2. Lippman ME, Dickson RB: Growth control of normal and malignant breast epithelium. Progr Clin Biol Res 3S4: 147–178, 1990

    Google Scholar 

  3. Reid SE, Murthy MS, Kaufman M, Scanlon EF: Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 83: 1037–1046, 1996

    Google Scholar 

  4. Spicer DV, Pike, MC: Breast cancer prevention through modulation of endogeneous hormones. Breast Cancer Res Treat 28: 179–193, 1993

    Google Scholar 

  5. Kelloff GJ, Lubet RA, Liberman R., Eisenhouer K, Steele V, Crowell JA, Hawk ET, Boone CW, Sigman CC: Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidem Biomark Prevention 7: 65–78, 1998

    Google Scholar 

  6. Meyer AS: Conversion of 19-hydroxy-4-androstene-3, 17-dione to estrone by endocrine tissue. Biochim Biophys Acta 17: 441–442, 1955

    Google Scholar 

  7. Cole PA, Robinson CH: Mechanism and inhibition of cytochrome P450 aromatase. J Med Chem 33: 2933–2942, 1990

    Google Scholar 

  8. Morano T, Hayano M, Dorfman RI, Axelrod LR: The intermediate steps in the biosynthesis of estrogens from androgenes. Biochem Biophys Res Comm 6: 334–338, 1961

    Google Scholar 

  9. Brodie AMH, Schwarzel WC, Brodie HJ: Studies on the mechanism of estrogen biosynthesis in the rat ovary-l. J Steroid Biochem 7: 787–793, 1976

    Google Scholar 

  10. Brodie AMH, Schwarzel WC, Shaikh AA, and Brodie HJ: The effect of an aromatase inhibitor, 4-Hydroxy-4-androstene-3,17-dione, on estrogen dependent processes in reproduction and breast cancer, Endocrinology 100: 1684–1695,1977

    Google Scholar 

  11. Bossche HV, Moereels H, Koymans LMH: Aromatase inhibitors-mechanisms for non-steroidal inhibitors, Breast Cancer Res Treat 30: 43–55, 1994

    Google Scholar 

  12. Lonning PE: Aromatase inhibitors and their future role in postmenopausal women with early breast cancer. Brit J Cancer 78 (4) 12–15, 1998

    Google Scholar 

  13. Demers DM, Lipton A, Harvey HA, Kambie KB, Gossberg H, Brady C, and Santen RJ: The effects of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced breast cancer, J Steroid Biochem Mol Biol 44: 687–691, 1993

    Google Scholar 

  14. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lonning PE: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286–1291, 1996

    Google Scholar 

  15. Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, Jeffery M, et al: Letrozole, a new potent selective aromatase inhibitor (AI)superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer previously treated with antiestrogens. J Clin Oncol 16: 156a, 1997

    Google Scholar 

  16. Goss PE: Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor, Breast Cancer Res Treat 49:1 S59–65, 1998

    Google Scholar 

  17. Boccardo F, Amoroso D, Tacobelli S, Irtelli L, Farris A, Mustacchi G, Mesiti M, Brema F, Pacini P. Cortesi E, Nordini P, Guida G, Langenaeken C: Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study. Ann Oncol 8: 745–750, 1997

    Google Scholar 

  18. Paridaens R, Roy JA, Nooij M, Klijn J, Houston SJ, Beex LV, Vinholes J, Tomiak E, Van Vreckem A, Langenaeken C, Van Glabbeke M, Piccart MJ, Vorozole (Rivizor): An active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational drug branch of the European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Cooperative Group. Anticancer Drugs 9: 29–35, 1998

    Google Scholar 

  19. Moon RC, Steele VE, Kelloff CJ, Thomas CF, Detrisac CJ, Mehta RG, Lubet RA: Chemoprevention of MNU-induced mammary carcinogenesis by hormone response modifiers: toremifene, RU16117, tamoxifen, aminoglutetamide, and progesterone. Anticancer Res 14: 889–893, 1994

    Google Scholar 

  20. Yue W, Zhou DJ, Chen S, and Brodie AMH: A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene, Cancer Res 54: 5092–5095, 1994

    Google Scholar 

  21. Lee K, Macaulay VM, Nicholls JE, Detre S, Ashworth A, Dowsett M: An in vivo model of intratumoral aromatase using aromatase transfected MCF-7 human breast cancer cells. Int J Cancer 62: 297–302, 1995

    Google Scholar 

  22. Lu Q, Yue W, Wang J, Liu Y, Long B, Brodie A: The effects of aromatase inhibitors and antiestrogens in the nude mouse model, Breast Cancer Res Treat 50: 63–71, 1998

    Google Scholar 

  23. Van Ginckel, R, Janssens B, Callens M, Goeminne N, Wouters L, De Coster R: Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7, 12-dimethylbenz(a)ntracene-induced mammary carcinoma in the rat. Cancer Chemotherapy Pharmacol 38: 21–28, 1996

    Google Scholar 

  24. De Coster R, VanGinkel RF, Callens MJL, Goeminne NKG, Janssens BLE: Antitumoral and endocrine effects of Vorozole in rats bearing dimethylbenzantrazen-induced mammary tumors. Cancer Res 52: 1240–1244, 1992

    Google Scholar 

  25. Lubet RA, Steele VE, Casebolt TL, Eto I, Kelloff GJ, Grubbs CJ: Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the MNUinduced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 15: 2775–2780, 1994

    Google Scholar 

  26. Lubet RA, Steele VE, DeCoster R, Bouden C, You M, Juliana MM, Eto, I, Kelloff GJ, Grubbs CJ: Chemopreventive effects of aromatase inhibitor vorozole (R83842) in the methylnitrosurea-induced mammary cancer model. Carcinogenesis 19: 1345–1351, 1998

    Google Scholar 

  27. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, Zwieten MJ: Comparative study on human and rat mammary tumorigenesis. Lab Investig 62: 244–278, 1990

    Google Scholar 

  28. Christov K, Swanson S, Guzmanm R, Thordarson G, Talamantes F, Nandi S: Cell proliferation and apoptosis during mammary carcinogenesis in pituitary isografted mice. Carcinogenesis 17: 1741–1746, 1996

    Google Scholar 

  29. Gavrielli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493–501, 1992

    Google Scholar 

  30. Wyllie AU: Apoptosis and the regulation of cell numbers in normal and neoplastic disease: an overview. Cancer and Metastasis Reviews 11: 95–103, 1992

    Google Scholar 

  31. Hickman JA. Apoptosis induced by anti-cancer drugs. Cancer Metast Rev 11: 121–139, 1992

    Google Scholar 

  32. Thompson CB: Apoptosis in pathogenesis and treatment of disease. Science 267: 1456–1462, 1995

    Google Scholar 

  33. Arafah BM, Finegan HM, Roe, JR., Manni A, Pearson OH: Hormone dependency in N-Nitrosourea-induced rat mammary tumors. Endocrinology 111: 584–588, 1982

    Google Scholar 

  34. Walker NI, Bennett RE, Kerr JFR: Cell death by apoptosis during involution of the lactating breast in mice and rats. Amer J Anatom 185: 19–32, 1989

    Google Scholar 

  35. Strange R, Li F, Saurer S, Burkhardt A. Fries RR: Apoptotic cell death and tissue remodeling during mouse mammary gland involution. Development 115: 49–58, 1992

    Google Scholar 

  36. Huovinen R, Warn A, Collan Y: Mitotic activity, apoptosis, and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer SS: 685–691, 1993

    Google Scholar 

  37. Snivastava P, Russo J, Russo IH: Chorionic gonadotropin inhibits rat mammary carcinogenesis through activation of programmed cell death. Carcinogenesis 18: 1799–1808, 1997

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, University of Illinois, Chicago, IL, USA

    Konstantin Christov, Anne Shilkaitis, Albert Green & Rajendra G. Mehta

  2. Chemoprevention Center, University of Alabama, Birmingham, AL, USA

    Clinton Grubbs

  3. NCI Chemoprevention Branch, Bethesda, MD, USA

    Gary Kelloff & Ronald Lubet

Authors
  1. Konstantin Christov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Shilkaitis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Albert Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rajendra G. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clinton Grubbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gary Kelloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ronald Lubet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christov, K., Shilkaitis, A., Green, A. et al. Cellular responses of mammary carcinomas to aromatase inhibitors: Effects of vorozole. Breast Cancer Res Treat 60, 117–128 (2000). https://doi.org/10.1023/A:1006384026252

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006384026252

Search

Navigation